Interpreting Adjuvant Therapy Trial Results in Advanced RCC
Before closing out their discussion on the evolving treatment landscape of advanced renal cell carcinoma, Matthew Campbell, MD, MS, and Brian Rini, MD, highlight clinical trials in the adjuvant setting.
Advanced Renal Cell Carcinoma: Nuancing Triplet Therapy Trial Results
Shared insight on the results from triplet therapy–centered clinical trials in advanced renal cell carcinoma and how these might inform treatment strategies as the paradigm continues to evolve.
Clinical Trial Data in Relapsed/Refractory Renal Cell Carcinoma
Experts Matthew Campbell, MD, MS, and Brian Rini, MD, provide a brief review of recent clinical data in the setting of relapsed/refractory renal cell carcinoma.
First-Line Clinical Trial Data in Advanced Renal Cell Carcinoma
A broad look at the data from several recent first-line clinical trials in the setting of advanced renal cell carcinoma and considerations for how they may impact real-world practice.
Renal Cell Carcinoma: Overlapping Toxicity in TKI/IO Combination Therapy
Closing out their discussion on adverse event management in advanced renal cell carcinoma, Matthew Campbell, MD, MS, and Brian Rini, MD, consider overlapping toxicity in TKI/IO regimens.
Adverse Event Management in Patients With Advanced RCC
Expert perspectives on the most common adverse events seen while managing advanced renal cell carcinoma, followed by advice on how best to manage these and counsel patients.
Factors in Selecting First-Line Therapy for Patients With Advanced RCC
Comprehensive insight on the factors that help determine optimal first-line therapy for a patient presenting with advanced renal cell carcinoma.
Advanced Renal Cell Carcinoma: An Evolving Treatment Armamentarium
Expert oncologists Matthew Campbell, MD, MS, and Brian Rini, MD, open their discussion on advanced renal cell carcinoma management by defining cornerstone treatment approaches.
Future Treatment Landscape of Metastatic Urothelial Carcinoma
Closing their discussion on metastatic urothelial carcinoma, panelists reflect on novel agents and the future treatment paradigm.
Selecting Second-Line Therapy for Metastatic Urothelial Carcinoma
Expert perspectives on the selection of second-line therapy after a patient has progressed on maintenance avelumab.
mUC: Duration of Maintenance Avelumab and Treatment at Progression
Focused discussion on the duration of maintenance avelumab for metastatic urothelial carcinoma and considerations for switching therapy.
Metastatic Urothelial Carcinoma: Does FGFR Status Impact Use of Maintenance Avelumab?
A brief review of whether FGFR status in metastatic urothelial carcinoma should impact treatment approaches.
Metastatic Urothelial Carcinoma: Discussing Maintenance Therapy With Patients
Shared insight on how best to discuss maintenance therapy with patients being treated for metastatic urothelial carcinoma.
When to Use Maintenance Therapy in Metastatic Urothelial Carcinoma
Panelists consider whether the use of maintenance therapy is as prevalent after complete response or in patients with lesser PD-L1 expression.
Metastatic Urothelial Carcinoma: Experience With Maintenance Avelumab
Experts highlight the benefits of frontline avelumab maintenance therapy in patients with metastatic urothelial carcinoma.
Frontline Immunotherapy for Metastatic Urothelial Carcinoma
Experts discuss frontline immunotherapy for metastatic urothelial carcinoma when chemotherapy may not be an option.
Metastatic Urothelial Carcinoma: Optimizing Frontline Maintenance Therapy
Shared insight on best practices in frontline maintenance therapy for metastatic urothelial carcinoma to improve patient outcomes.
Selecting Frontline Therapy for Metastatic Urothelial Carcinoma
Reviewing a patient case of metastatic urothelial carcinoma, experts discuss the selection of frontline and maintenance therapy.
2 Clarke Drive Cranbury, NJ 08512